248 related articles for article (PubMed ID: 21291269)
1. Discovery of a potential allosteric ligand binding site in CDK2.
Betzi S; Alam R; Martin M; Lubbers DJ; Han H; Jakkaraj SR; Georg GI; Schönbrunn E
ACS Chem Biol; 2011 May; 6(5):492-501. PubMed ID: 21291269
[TBL] [Abstract][Full Text] [Related]
2. A novel approach to the discovery of small-molecule ligands of CDK2.
Martin MP; Alam R; Betzi S; Ingles DJ; Zhu JY; Schönbrunn E
Chembiochem; 2012 Sep; 13(14):2128-36. PubMed ID: 22893598
[TBL] [Abstract][Full Text] [Related]
3. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2.
Li Y; Zhang J; Gao W; Zhang L; Pan Y; Zhang S; Wang Y
Int J Mol Sci; 2015 Apr; 16(5):9314-40. PubMed ID: 25918937
[TBL] [Abstract][Full Text] [Related]
4. Cooperativity Between Orthosteric Inhibitors and Allosteric Inhibitor 8-Anilino-1-Naphthalene Sulfonic Acid (ANS) in Cyclin-Dependent Kinase 2.
Faber EB; Tian D; Burban D; Levinson NM; Hawkinson JE; Georg GI
ACS Chem Biol; 2020 Jul; 15(7):1759-1764. PubMed ID: 32433863
[TBL] [Abstract][Full Text] [Related]
5. Specific Conformational Dynamics and Expansion Underpin a Multi-Step Mechanism for Specific Binding of p27 with Cdk2/Cyclin A.
Tsytlonok M; Hemmen K; Hamilton G; Kolimi N; Felekyan S; Seidel CAM; Tompa P; Sanabria H
J Mol Biol; 2020 Apr; 432(9):2998-3017. PubMed ID: 32088186
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel nonpeptide allosteric inhibitors interrupting the interaction of CDK2/cyclin A3 by virtual screening and bioassays.
Hu Y; Li S; Liu F; Geng L; Shu X; Zhang J
Bioorg Med Chem Lett; 2015 Oct; 25(19):4069-73. PubMed ID: 26316466
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the ORC1-Cyclin A association.
Wang B; Song J
Protein Sci; 2019 Sep; 28(9):1727-1733. PubMed ID: 31309634
[TBL] [Abstract][Full Text] [Related]
8. Conformational Equilibrium of CDK/Cyclin Complexes by Molecular Dynamics with Excited Normal Modes.
Floquet N; Costa MG; Batista PR; Renault P; Bisch PM; Raussin F; Martinez J; Morris MC; Perahia D
Biophys J; 2015 Sep; 109(6):1179-89. PubMed ID: 26255588
[TBL] [Abstract][Full Text] [Related]
9. Molecular Dynamics Simulations and Classical Multidimensional Scaling Unveil New Metastable States in the Conformational Landscape of CDK2.
Pisani P; Caporuscio F; Carlino L; Rastelli G
PLoS One; 2016; 11(4):e0154066. PubMed ID: 27100206
[TBL] [Abstract][Full Text] [Related]
10. Type II Inhibitors Targeting CDK2.
Alexander LT; Möbitz H; Drueckes P; Savitsky P; Fedorov O; Elkins JM; Deane CM; Cowan-Jacob SW; Knapp S
ACS Chem Biol; 2015 Sep; 10(9):2116-25. PubMed ID: 26158339
[TBL] [Abstract][Full Text] [Related]
11. SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2.
Moshinsky DJ; Bellamacina CR; Boisvert DC; Huang P; Hui T; Jancarik J; Kim SH; Rice AG
Biochem Biophys Res Commun; 2003 Oct; 310(3):1026-31. PubMed ID: 14550307
[TBL] [Abstract][Full Text] [Related]
12. Critical role for the 310 helix region of p57(Kip2) in cyclin-dependent kinase 2 inhibition and growth suppression.
Hashimoto Y; Kohri K; Kaneko Y; Morisaki H; Kato T; Ikeda K; Nakanishi M
J Biol Chem; 1998 Jun; 273(26):16544-50. PubMed ID: 9632724
[TBL] [Abstract][Full Text] [Related]
13. Site-directed mutant p21 proteins defective in both inhibition of E2F-regulated transcription and disruption of E2F-p130-cyclin-cdk2 complexes.
Robles SJ; Shiyanov P; Aristodemo GT; Raychaudhuri P; Adami GR
DNA Cell Biol; 1998 Jan; 17(1):9-18. PubMed ID: 9468218
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of a viral cyclin, a positive regulator of cyclin-dependent kinase 6.
Schulze-Gahmen U; Jung JU; Kim SH
Structure; 1999 Mar; 7(3):245-54. PubMed ID: 10368294
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division.
Lacy ER; Wang Y; Post J; Nourse A; Webb W; Mapelli M; Musacchio A; Siuzdak G; Kriwacki RW
J Mol Biol; 2005 Jun; 349(4):764-73. PubMed ID: 15890360
[TBL] [Abstract][Full Text] [Related]
16. Structure-based approaches to improve selectivity: CDK2-GSK3beta binding site analysis.
Vulpetti A; Crivori P; Cameron A; Bertrand J; Brasca MG; D'Alessio R; Pevarello P
J Chem Inf Model; 2005; 45(5):1282-90. PubMed ID: 16180905
[TBL] [Abstract][Full Text] [Related]
17. Role of phosphorylated Thr160 for the activation of the CDK2/Cyclin A complex.
De Vivo M; Cavalli A; Bottegoni G; Carloni P; Recanatini M
Proteins; 2006 Jan; 62(1):89-98. PubMed ID: 16292742
[TBL] [Abstract][Full Text] [Related]
18. Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics.
Otyepka M; Bártová I; Kríz Z; Koca J
J Biol Chem; 2006 Mar; 281(11):7271-81. PubMed ID: 16407256
[TBL] [Abstract][Full Text] [Related]
19. A flexible-protein molecular docking study of the binding of ruthenium complex compounds to PIM1, GSK-3β, and CDK2/Cyclin A protein kinases.
Liu Y; Agrawal NJ; Radhakrishnan R
J Mol Model; 2013 Jan; 19(1):371-82. PubMed ID: 22926267
[TBL] [Abstract][Full Text] [Related]
20. Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies.
Noble ME; Endicott JA
Pharmacol Ther; 1999; 82(2-3):269-78. PubMed ID: 10454204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]